Welcome to our dedicated page for Perimeter Medical Imaging Ai news (Ticker: PYNKF), a resource for investors and traders seeking the latest updates and insights on Perimeter Medical Imaging Ai stock.
Overview
Perimeter Medical Imaging AI Inc is a commercial-stage medical technology company dedicated to transforming cancer surgery through ultra-high-resolution, real-time imaging solutions. The company specializes in advanced optical coherence tomography (OCT) and artificial intelligence (AI) systems, enabling surgical teams to visualize tissues at a cellular level during operations. Its FDA-cleared S-Series OCT system and the investigational B-Series OCT with ImgAssist AI represent a significant advancement in intraoperative imaging, directly addressing the challenge of accurately determining surgical margins and reducing re-excision rates.
Core Technologies and Applications
At the heart of Perimeter's offerings is its state-of-the-art OCT technology, which leverages light to capture detailed, cross-sectional images of excised tissues. This technology provides real-time visual feedback in the operating room, offering surgeons a powerful tool for margin assessment during procedures such as breast-conserving surgeries. By integrating proprietary AI algorithms through its ImgAssist system, Perimeter enhances the imaging process to detect residual cancer with greater precision compared to traditional methods like X-ray, ultrasound, or MRI.
The company’s clinical applications focus on:
- Surgical Margin Visualization: Enabling surgeons to identify regions of interest and determine the adequacy of surgical resection in real-time.
- Intraoperative Decision Support: Assisting with margin evaluation during procedures, potentially minimizing the likelihood of repeat surgeries.
- Advanced Imaging in Oncology: Meeting a critical need in cancer surgery by providing high-resolution images that enhance clinical outcomes.
Industry Context and Market Position
Operating within the highly competitive medical imaging and surgical technology industry, Perimeter Medical Imaging AI leverages its expertise in both hardware and software to offer breakthrough diagnostic tools. The integration of AI with real-time imaging distinguishes the company from traditional imaging providers by offering enhanced decision support in the surgical environment. This dual approach not only supports more precise surgical interventions but also underlines the company’s commitment to addressing significant unmet clinical needs.
Perimeter’s technology is designed to integrate seamlessly into existing surgical workflows. Its products have been showcased at international conferences and are supported by rigorous clinical trials, which are instrumental in cementing its reputation for clinical validation and technological innovation. The company’s advancements contribute to improved patient care by potentially improving surgical outcomes and reducing healthcare costs associated with reoperations.
Business Model and Operational Excellence
Perimeter Medical Imaging AI generates revenue from several streams including direct device sales, consumables, system leases, and potential licensing opportunities. The company’s strategic focus on clinical trials and surgeon education is central to driving market adoption. By collaborating with healthcare providers and leveraging grant funding to support clinical research, Perimeter aims to validate its technology and build a robust user base within key market segments.
The operational excellence of Perimeter is underscored by its ability to integrate clinical insights with advanced technological solutions. The company continuously develops and refines its products to meet the practical needs of the surgical community, ensuring that its imaging tools remain at the forefront of innovation in cancer surgery.
Commitment to Expertise, Experience, and Trust
Perimeter Medical Imaging AI upholds stringent standards of quality and clinical validation. This commitment is reflected in its extensive efforts in clinical trials, regulatory approvals, and the incorporation of feedback from leading surgical oncologists. The company’s leadership combines rich experience in the fields of medical technology and AI, lending credibility and depth to its innovations. Detailed clinical studies and rigorous testing protocols enhance the transparency and reliability of its imaging systems.
By fostering ongoing research and maintaining a proactive approach to technological development, Perimeter establishes itself as an authoritative source of innovation in intraoperative imaging. This approach not only demonstrates deep industry knowledge but also builds enduring trust among healthcare providers, investors, and other stakeholders.
Competitive Differentiation
Unlike traditional imaging methods, Perimeter’s solutions provide surgeons with immediate, actionable insights during operations. The company differentiates itself through a combination of high-resolution imaging and AI-driven interpretation, which together enhance the accuracy and efficiency of margin assessments. This differentiation is supported by:
- Robust clinical validation through pivotal trials.
- Strategic partnerships and active participation in international medical conferences.
- An extensive proprietary image data set that fuels continuous AI model improvement.
Conclusion
Perimeter Medical Imaging AI Inc is a pioneer in employing advanced OCT and AI technologies to redefine the standards of cancer surgery. Its innovative platforms support surgeons in making well-informed, real-time decisions that potentially reduce the risk of reoperations and improve overall patient outcomes. Through its commitment to deep clinical validation, technological rigor, and continuous innovation, Perimeter maintains its position as a significant and trustworthy contributor to the field of surgical imaging.
Perimeter Medical Imaging AI, Inc. (TSX-V:PINK, OTC:PYNKF) announced the outcomes of its annual shareholder meeting held on October 27, 2021. Shareholders approved all resolutions, including the re-election of nine directors and the reappointment of KPMG LLP as auditors. Additionally, the stock option plan was amended to increase common shares reserved for issuance. The company granted 1,949,663 stock options at $2.85 each. Perimeter continues to advance its imaging technologies for cancer surgery, including the FDA-cleared S-Series OCT and the ImgAssist AI project.
Perimeter Medical Imaging AI (TSX-V:PINK, OTC:PYNKF) will participate in the LD Micro Main Event Investor Conference from October 12-14, 2021, in Los Angeles, CA. CEO Jeremy Sobotta will present on October 12 at 3:30 pm PT. Perimeter's S-Series Optical Coherence Tomography (OCT) is FDA-cleared and offers real-time tissue visualization, potentially improving patient outcomes. The company is also developing the B-Series OCT with ImgAssist AI, funded by a $7.4 million grant from CPRIT, aimed at reducing re-operation rates in breast cancer surgeries.
Perimeter Medical Imaging AI (TSX-V:PINK, OTC:PYNKF) will present at the Lytham Partners Fall 2021 Investor Conference on October 5, 2021, at 12:30 p.m. ET. The conference aims to showcase Perimeter's advanced imaging technologies designed to enhance cancer surgery outcomes. A webcast of the presentation will be available on their website. Management will also conduct virtual one-on-one meetings during the event, running from October 5-7. Perimeter is known for its S-Series OCT and B-Series OCT with ImgAssist AI technology.
Perimeter Medical Imaging AI, a medical technology company, announced its participation in upcoming industry events focused on cancer surgery and advanced imaging tools. Key highlights include Dr. Anthony Lucci's presentation on Optical Coherence Tomography at Mayo Clinic on September 17, 2021, and a poster presentation at the College of American Pathologists Annual Meeting from September 25-28, 2021. The CEO emphasized the importance of showcasing the Perimeter S-Series OCT system, which provides real-time visualization of excised tissue. The company is also advancing its B-Series OCT with ImgAssist AI, backed by a $7.4 million grant.
Perimeter Medical Imaging AI reported its Q2 2021 financial results, highlighting a net loss of $3.24 million, a decrease from $4.66 million in Q2 2020. Operating expenses increased to $3.06 million from $2 million in the previous year. Key developments included the U.S. FDA granting Breakthrough Device Designation for its imaging systems, the achievement of a 0.94 AUC in its ImgAssist AI algorithm, and plans for a pivotal study aimed at reducing breast cancer re-operation rates.
Perimeter Medical Imaging AI, Inc. (TSX-V:PINK)(OTC:PYNKF) announced significant progress in expanding its commercial organization, led by Chief Commercial Officer Steve Sapot. The company has hired four experienced market development managers to promote its S-Series OCT medical imaging technology in the U.S. market. Perimeter's innovative imaging system, cleared by the U.S. FDA, aims to enhance cancer surgery outcomes and reduce healthcare costs. Additionally, the company is advancing its ImgAssist AI technology under the ATLAS AI project, supported by a US$7.4 million grant.
Perimeter Medical Imaging AI, Inc. (TSX-V:PINK)(OTC:PYNKF) has announced that its common shares are now eligible for electronic clearing and settlement through The Depository Trust Company (DTC) in the U.S. This DTC eligibility aims to increase liquidity and enhance the company's presence in U.S. capital markets. CEO Jeremy Sobotta highlighted the benefits for existing shareholders, including faster execution speeds and greater opportunities to attract new investors. The company's imaging technology, including S-Series and B-Series OCT systems, is designed to improve cancer surgery outcomes.
Perimeter Medical Imaging AI (OTC:PYNKF), a leader in medical imaging technology, will participate in the 6th Annual Needham Virtual Med Tech & Diagnostics Conference on August 16-17, 2021. CEO Jeremy Sobotta will hold one-on-one virtual meetings during the event. Perimeter's FDA-cleared S-Series Optical Coherence Tomography (OCT) offers real-time visualization of excised tissue, potentially enhancing surgical outcomes. The company is also developing the B-Series OCT with ImgAssist AI, backed by a $7.4 million CPRIT grant, aimed at improving breast conservation surgery outcomes.
Perimeter Medical Imaging AI (TSX-V:PINK)(OTC:PYNKF) has appointed Dr. Sarah Butler as Vice President of Clinical and Medical Affairs, effective immediately. CEO Jeremy Sobotta expressed enthusiasm over Butler's expertise in medical affairs, expecting her to enhance clinical strategies as the company prepares for a pivotal study of its ImgAssist AI software. Dr. Butler brings extensive experience from previous roles, including her tenure at IBM Watson Health. The company focuses on transforming cancer surgery with advanced imaging tools, addressing unmet medical needs.
Perimeter Medical Imaging AI (TSX-V: PINK, OTC: PYNKF) announced CEO Jeremy Sobotta will participate in the virtual Lytham Partners Summer 2021 Investor Conference panel on breast cancer innovations on June 15, 2021, at 5:00 PM ET. The event runs from June 14-16, 2021, with one-on-one meetings available. Perimeter's FDA-cleared S-Series Optical Coherence Tomography (OCT) enhances real-time visualization during surgery, aiming for improved patient outcomes. The B-Series OCT, supported by a $7.4 million CPRIT grant, is set for a pivotal study to evaluate its impact on breast cancer surgery.
FAQ
What is the current stock price of Perimeter Medical Imaging Ai (PYNKF)?
What is the market cap of Perimeter Medical Imaging Ai (PYNKF)?
What does Perimeter Medical Imaging AI Inc specialize in?
What are the core products offered by the company?
How does the company improve surgical outcomes?
What role does artificial intelligence play in their technology?
In which market segments does Perimeter operate?
How does the company support clinical validation for its products?
What differentiates Perimeter's technology from traditional imaging methods?
How does Perimeter generate revenue?
Where is Perimeter Medical Imaging AI Inc headquartered?
